Wikidata |

Wikidata

Matches in Wikidata for { <http://www.wikidata.org/entity/Q57579457> ?p ?o ?g. }

Showing items 1 to 100 of ±109 with 100 items per page.

Q57579457 description "article scientifique publié en 2014" @default.
Q57579457 description "artículu científicu espublizáu en setiembre de 2014" @default.
Q57579457 description "im September 2014 veröffentlicher wissenschaftlicher Artikel" @default.
Q57579457 description "scientific article published on 28 September 2014" @default.
Q57579457 description "wetenschappelijk artikel" @default.
Q57579457 description "наукова стаття, опублікована в жовтні 2014" @default.
Q57579457 name "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 name "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 type Item @default.
Q57579457 label "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 label "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 prefLabel "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 prefLabel "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando" @default.
Q57579457 P1433 Q57579457-C9718178-A7EE-43FD-AEC5-DDE941646242 @default.
Q57579457 P1476 Q57579457-5B252401-2D7A-40DC-96C4-B341D6C3B50E @default.
Q57579457 P2093 Q57579457-2180CE1F-1B19-4507-9FFC-A62C8466A177 @default.
Q57579457 P2093 Q57579457-46B5DE06-5F4E-4D04-9907-4298A5D6D90A @default.
Q57579457 P2093 Q57579457-7CD6AB20-6CF2-4E28-B6B7-A124D9A70146 @default.
Q57579457 P2093 Q57579457-8A66D401-C71A-40AE-8C1F-237F737D8F66 @default.
Q57579457 P2093 Q57579457-A1CE7F17-013B-4ED0-936B-8C2B62B0959E @default.
Q57579457 P2093 Q57579457-AD93E93C-C3A0-4AFA-94A8-632005A23251 @default.
Q57579457 P2093 Q57579457-C9E53490-E96B-4495-891B-99DB187E7670 @default.
Q57579457 P2093 Q57579457-CEFBD101-9BFD-4DF0-A070-64021FDB4DD5 @default.
Q57579457 P2093 Q57579457-DDDCD79D-A6B7-4606-8365-A7563F2F6450 @default.
Q57579457 P2093 Q57579457-F2026F70-0FD7-46A5-B0D1-3FF3A580A7B8 @default.
Q57579457 P2093 Q57579457-FCF85244-65DD-4C5D-9E2B-6E4E33134428 @default.
Q57579457 P2860 Q57579457-08D4529B-A300-442C-BEC5-7FA977C3E35B @default.
Q57579457 P2860 Q57579457-30C13E92-5A37-4B03-8E27-DD695E506390 @default.
Q57579457 P2860 Q57579457-30EFA6F1-FFBC-481C-8334-73ED9712A95F @default.
Q57579457 P2860 Q57579457-386E9EDB-D292-4B97-A632-803BB3BF32B4 @default.
Q57579457 P2860 Q57579457-4AF0C946-0C32-4B38-8A36-0FF1448C8AF7 @default.
Q57579457 P2860 Q57579457-4B37801E-ED2D-4DC9-8593-81503E67795D @default.
Q57579457 P2860 Q57579457-63AF6F8F-4706-4F8C-987F-1F73B2C18672 @default.
Q57579457 P2860 Q57579457-7F31E47B-5251-4E2D-A66C-ECB4A98F3263 @default.
Q57579457 P2860 Q57579457-8F8DD0E9-EFF1-4ED6-A06F-9471A021FE47 @default.
Q57579457 P2860 Q57579457-91C7F5EC-43B7-45DD-858D-E6899EF4C2E1 @default.
Q57579457 P2860 Q57579457-A560C768-A47A-4E51-A816-BD07070262F7 @default.
Q57579457 P2860 Q57579457-B2639C9E-6895-4803-B463-086DEA7CF0F2 @default.
Q57579457 P2860 Q57579457-C6B3E04D-7AAF-425B-9E9C-DBAAF649541B @default.
Q57579457 P2860 Q57579457-D58F6944-7CCB-4ADD-978F-F5A2BED5FF85 @default.
Q57579457 P2860 Q57579457-D64E100E-83B2-4633-BBA1-891BA350EE5C @default.
Q57579457 P2860 Q57579457-DCB6DFFA-6ABF-4F70-9625-692BB0C59DD2 @default.
Q57579457 P2860 Q57579457-DF2B10F6-EE5A-45C7-8662-8FE68343CF77 @default.
Q57579457 P2860 Q57579457-E2593AB4-CFCC-47AD-AEDF-6EA29F090070 @default.
Q57579457 P2860 Q57579457-FC6847FA-EEBB-4A97-9E57-F051B09964B8 @default.
Q57579457 P304 Q57579457-074C976D-60FB-46D2-8867-DACEB20A1BC4 @default.
Q57579457 P31 Q57579457-E49F6FC0-0311-4BF3-8BF4-1D3D94747529 @default.
Q57579457 P356 Q57579457-1DF1964B-FA73-4C83-9084-F742C94A0DAF @default.
Q57579457 P433 Q57579457-A3291B8E-17B1-4208-A162-0248AE09A109 @default.
Q57579457 P478 Q57579457-AC3850BB-820C-42E9-B51B-5CE80DC0C993 @default.
Q57579457 P50 Q57579457-1BBD5186-C43A-44AA-9BAC-066B67180B04 @default.
Q57579457 P50 Q57579457-1ECED9E3-A4E5-4F0E-91C9-88663BFAFFD3 @default.
Q57579457 P50 Q57579457-55505C0A-3146-46E2-9619-D160F544FB83 @default.
Q57579457 P50 Q57579457-950371A2-E7CF-4A29-B450-311ED24A4C6B @default.
Q57579457 P50 Q57579457-B04771B6-8BAF-4F77-A88F-E6C059121C8E @default.
Q57579457 P577 Q57579457-FCE9D4BF-6D06-4B86-952A-5B9097C8A9A1 @default.
Q57579457 P698 Q57579457-E070179B-0991-4389-BC76-A93A51CD402F @default.
Q57579457 P921 Q57579457-1D189841-E1F8-4DC3-93DF-35638DE41F36 @default.
Q57579457 P921 Q57579457-E534DB13-F253-4BB0-B5CD-EF8200B37420 @default.
Q57579457 P921 Q57579457-E6BE43AA-7AB8-46B1-AA36-4C482EB2599F @default.
Q57579457 P356 S1470-2045(14)70439-5 @default.
Q57579457 P698 25273342 @default.
Q57579457 P1433 Q13747613 @default.
Q57579457 P1476 "Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial" @default.
Q57579457 P2093 "Christoph Zielinski" @default.
Q57579457 P2093 "Corinne Veyret" @default.
Q57579457 P2093 "Cristian Villanueva" @default.
Q57579457 P2093 "Eduard Vrdoljak" @default.
Q57579457 P2093 "Gilles Romieu" @default.
Q57579457 P2093 "Gunter von Minckwitz" @default.
Q57579457 P2093 "István Lang" @default.
Q57579457 P2093 "Norbert Marschner" @default.
Q57579457 P2093 "Sabine de Ducla" @default.
Q57579457 P2093 "Stefanie Srock" @default.
Q57579457 P2093 "Ulrich Freudensprung" @default.
Q57579457 P2860 Q27851468 @default.
Q57579457 P2860 Q29614302 @default.
Q57579457 P2860 Q34022546 @default.
Q57579457 P2860 Q34638749 @default.
Q57579457 P2860 Q34645599 @default.
Q57579457 P2860 Q37231532 @default.
Q57579457 P2860 Q37259271 @default.
Q57579457 P2860 Q37909171 @default.
Q57579457 P2860 Q39173162 @default.
Q57579457 P2860 Q39691997 @default.
Q57579457 P2860 Q43790301 @default.
Q57579457 P2860 Q44963911 @default.
Q57579457 P2860 Q51762694 @default.
Q57579457 P2860 Q54523915 @default.
Q57579457 P2860 Q71721709 @default.
Q57579457 P2860 Q82294729 @default.
Q57579457 P2860 Q84735057 @default.
Q57579457 P2860 Q85077949 @default.
Q57579457 P2860 Q87880547 @default.
Q57579457 P304 "1269-1278" @default.
Q57579457 P31 Q13442814 @default.
Q57579457 P356 "10.1016/S1470-2045(14)70439-5" @default.
Q57579457 P433 "11" @default.
Q57579457 P478 "15" @default.
Q57579457 P50 Q39600020 @default.